Skip to main content

Drug Interactions between deuruxolitinib and sodium phosphate p32

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sodium phosphate p32 deuruxolitinib

Applies to: sodium phosphate p32 and deuruxolitinib

MONITOR: The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.

MANAGEMENT: Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Sodium phosphate P-32 should not be used as part of a sequential treatment with a chemotherapeutic agent. Dose reductions of the other bone marrow depressants may be necessary. The manufacturer's labeling should be consulted for more specific recommendations for each agent involved. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References (1)
  1. AnazaoHealth Corporation (2023) P32 sodium phosphate - p32 sodium phosphate solution https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78&type=display

Drug and food/lifestyle interactions

Moderate

deuruxolitinib food/lifestyle

Applies to: deuruxolitinib

MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.

References (1)
  1. (2024) "Product Information. Leqselvi (deuruxolitinib)." Sun Pharmaceutical Industries

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer